{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:29:29Z","timestamp":1781245769534,"version":"3.54.1"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T00:00:00Z","timestamp":1614038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s40266-021-00838-6","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T02:02:46Z","timestamp":1614045766000},"page":"265-284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic Recommendations for the Management of Older Adult Patients with Sj\u00f6gren\u2019s Syndrome"],"prefix":"10.1007","volume":"38","author":[{"given":"Soledad","family":"Retamozo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrika","family":"Bootsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"De Vita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin A.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques-Eric","family":"Gottenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hern\u00e1ndez-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Kocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belchin","family":"Kostov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aike A.","family":"Kruize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mandl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Fai","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00e8le","family":"Seror","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Shoenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Sis\u00f3-Almirall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios G.","family":"Tzioufas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Vissink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Bowman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Ramos-Casals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Brito-Zer\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,23]]},"reference":[{"key":"838_CR1","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","volume":"378","author":"X Mariette","year":"2018","unstructured":"Mariette X, Criswell LA. Primary Sj\u00f6gren\u2019s syndrome. N Engl J Med. 2018;378:931\u20139.","journal-title":"N Engl J Med"},{"key":"838_CR2","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","volume":"2","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Baldini C, Bootsma H, et al. Sj\u00f6gren syndrome. Nat Rev Dis Primers. 2016;2:16047.","journal-title":"Nat Rev Dis Primers."},{"key":"838_CR3","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3109\/03009742.2014.931457","volume":"44","author":"M Kvarnstrom","year":"2015","unstructured":"Kvarnstrom M, Ottosson V, Nordmark B, et al. Incident cases of primary Sj\u00f6gren\u2019s syndrome during a 5-year period in Stockholm County: a descriptive study of the patients and their characteristics. Scand J Rheumatol. 2015;44:135\u201342.","journal-title":"Scand J Rheumatol"},{"key":"838_CR4","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3899\/jrheum.100883","volume":"38","author":"MY Weng","year":"2011","unstructured":"Weng MY, Huang YT, Liu MF, et al. Incidence and mortality of treated primary Sj\u00f6gren\u2019s syndrome in Taiwan: a population-based study. J Rheumatol. 2011;38:706\u20138.","journal-title":"J Rheumatol"},{"key":"838_CR5","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/03009740600759704","volume":"35","author":"Y Kabasakal","year":"2006","unstructured":"Kabasakal Y, Kitapcioglu G, Turk T, et al. The prevalence of Sj\u00f6gren\u2019s syndrome in adult women. Scand J Rheumatol. 2006;35:379\u201383.","journal-title":"Scand J Rheumatol"},{"key":"838_CR6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.22115","volume":"66","author":"C Maldini","year":"2014","unstructured":"Maldini C, Seror R, Fain O, et al. Epidemiology of primary Sj\u00f6gren\u2019s syndrome in a French multiracial\/multiethnic area. Arthritis Care Res. (Hoboken). 2014;66:454\u201363.","journal-title":"Arthritis Care Res. (Hoboken)"},{"key":"838_CR7","doi-asserted-by":"crossref","first-page":"e3821","DOI":"10.1136\/bmj.e3821","volume":"344","author":"M Ramos-Casals","year":"2012","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Sis\u00f3-Almirall A, et al. Primary Sjogren syndrome. BMJ. 2012;344:e3821.","journal-title":"BMJ"},{"key":"838_CR8","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40266-013-0050-7","volume":"30","author":"RV Moerman","year":"2013","unstructured":"Moerman RV, Bootsma H, Kroese FGM, et al. Sj\u00f6gren\u2019s syndrome in older patients: aetiology, diagnosis and management. Drugs Aging. 2013;30:137\u201353.","journal-title":"Drugs Aging"},{"key":"838_CR9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-016-0153-9","volume":"17","author":"A Wolff","year":"2017","unstructured":"Wolff A, Joshi RK, Ekstr\u00f6m J, et al. A guide to medications inducing salivary gland dysfunction, xerostomia, and subjective sialorrhea: a systematic review sponsored by the world workshop on oral medicine VI. Drugs R D. 2017;17:1\u201328.","journal-title":"Drugs R D."},{"key":"838_CR10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1754-4505.1996.tb00842.x","volume":"16","author":"A Vissink","year":"1996","unstructured":"Vissink A, Spijkervet FK, Van Nieuw Amerongen A. Aging and saliva: a review of the literature. Spec Care Dent. 1996;16:95\u2013103.","journal-title":"Spec Care Dent."},{"key":"838_CR11","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1532-5415.2002.50123.x","volume":"50","author":"JA Ship","year":"2002","unstructured":"Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc. 2002;50:535\u201343.","journal-title":"J Am Geriatr Soc"},{"key":"838_CR12","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1177\/014556139907800707","volume":"78","author":"FC Astor","year":"1999","unstructured":"Astor FC, Hanft KL, Ciocon JO. Xerostomia: a prevalent condition in the elderly. Ear Nose Throat J. 1999;78:476\u20139.","journal-title":"Ear Nose Throat J"},{"key":"838_CR13","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cden.2019.06.003","volume":"63","author":"L Marchini","year":"2019","unstructured":"Marchini L, Ettinger R, Hartshorn J. Personalized dental caries management for frail older adults and persons with special needs. Dent Clin North Am. 2019;63:631\u201351.","journal-title":"Dent Clin North Am"},{"key":"838_CR14","first-page":"795","volume":"28","author":"M Tishler","year":"2001","unstructured":"Tishler M, Yaron I, Shirazi I, et al. Clinical and immunological characteristics of elderly onset Sj\u00f6gren\u2019s syndrome: a comparison with younger onset disease. J Rheumatol. 2001;28:795\u20137.","journal-title":"J Rheumatol"},{"key":"838_CR15","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/rheumatology\/kez578","volume":"59","author":"P Brito-Zer\u00f3n","year":"2020","unstructured":"Brito-Zer\u00f3n P, Acar-Denizli N, Ng WF, et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford). 2020;59:2350\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"838_CR16","doi-asserted-by":"crossref","unstructured":"Ramos-Casals M, Brito-Zer\u00f3n P, Bombardieri S, et al; EULAR-Sj\u00f6gren Syndrome Task Force Group. EULAR recommendations for the management of Sj\u00f6gren\u2019s syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79:3\u201318.","DOI":"10.1136\/annrheumdis-2019-216114"},{"key":"838_CR17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.archoralbio.2016.05.001","volume":"69","author":"EM Varoni","year":"2016","unstructured":"Varoni EM, Federighi V, Decani S, et al. The effect of clinical setting on the unstimulated salivary flow rate. Arch Oral Biol. 2016;69:7\u201312.","journal-title":"Arch Oral Biol"},{"key":"838_CR18","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4047\/jap.2015.7.2.93","volume":"7","author":"B Oncul","year":"2015","unstructured":"Oncul B, Karakis D, Dogruman F. The effect of two artificial salivas on the adhesion of Candida albicans to heat polymerized acrylic resin. J Adv Prosthodont. 2015;7:93\u20137.","journal-title":"J Adv Prosthodont."},{"key":"838_CR19","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/ger.12034","volume":"31","author":"G G\u00f3mez-Moreno","year":"2014","unstructured":"G\u00f3mez-Moreno G, Cabrera-Ayala M, Aguilar-Salvatierra A, et al. Evaluation of the efficacy of a topical sialogogue spray containing malic acid 1% in elderly people with xerostomia: a double-blind, randomized clinical trial. Gerodontology. 2014;31:274\u201380.","journal-title":"Gerodontology."},{"key":"838_CR20","doi-asserted-by":"crossref","unstructured":"Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dentril Assoc. 1987;115:581\u2013584.","DOI":"10.1016\/S0002-8177(87)54012-0"},{"key":"838_CR21","first-page":"12","volume":"16","author":"WM Thomson","year":"1999","unstructured":"Thomson WM, Chalmers JM, Spencer AJ, et al. The Xerostomia inventory: a multi-item approach to measuring dry mouth. Community Dent Health. 1999;16:12\u20137.","journal-title":"Community Dent Health"},{"key":"838_CR22","unstructured":"Choroma\u0144ska M, Klimiuk A, Kostecka-Socho\u0144 P, et al. Antioxidant defence, oxidative stress and oxidative damage in saliva, plasma and erythrocytes of dementia patients. Can salivary AGE be a marker of dementia? Int J Mol Sci. 2017;18:2205."},{"key":"838_CR23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ageing\/28.6.557","volume":"28","author":"D Fischer","year":"1999","unstructured":"Fischer D, Ship JA. Effect of age on variability of parotid salivary gland flow rates over time. Age Ageing. 1999;28:557\u201361.","journal-title":"Age Ageing"},{"key":"838_CR24","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1177\/00220345920710120401","volume":"71","author":"TO N\u00e4rhi","year":"1992","unstructured":"N\u00e4rhi TO, Meurman JH, Ainamo A, et al. Association between salivary flow rate and the use of systemic medication among 76-, 81-, and 86-year-old inhabitants in Helsinki, Finland. J Dent Res. 1992;71:1875\u201380.","journal-title":"J Dent Res."},{"key":"838_CR25","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jgs.12219","volume":"61","author":"CH Smith","year":"2013","unstructured":"Smith CH, Boland B, Daureeawoo Y, et al. Effect of aging on stimulated salivary flow in adults. J Am Geriatr Soc. 2013;61:805\u20138.","journal-title":"J Am Geriatr Soc"},{"key":"838_CR26","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1111\/jgs.13652","volume":"63","author":"RH Affoo","year":"2015","unstructured":"Affoo RH, Foley N, Garrick R, et al. Meta-analysis of salivary flow rates in young and older adults. J Am Geriatr Soc. 2015;63:2142\u201351.","journal-title":"J Am Geriatr Soc"},{"key":"838_CR27","first-page":"149","volume":"58","author":"H Kagami","year":"1995","unstructured":"Kagami H, Hayashi T, Shigetomi T, et al. Assessment of the effects of aging and medication on salivary gland function in patients with xerostomia using 99mTC-scintigraphy. Clin Trial Nagoya J Med Sci. 1995;58:149\u201355.","journal-title":"Clin Trial Nagoya J Med Sci."},{"key":"838_CR28","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/ger.12319","volume":"35","author":"M Iwasaki","year":"2018","unstructured":"Iwasaki M, Borgnakke WS, Yoshihara A, et al. Hyposalivation and 10-year all-cause mortality in an elderly Japanese population. Gerodontology. 2018;35:87\u201394.","journal-title":"Gerodontology."},{"key":"838_CR29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1754-4505.1989.tb01013.x","volume":"9","author":"SL Handelman","year":"1989","unstructured":"Handelman SL, Baric JM, Saunders RH, et al. Hyposalivatory drug use, whole stimulated salivary flow, and mouth dryness in older, long-term care residents. Spec Care Dentist. 1989;9:12\u20138.","journal-title":"Spec Care Dentist"},{"key":"838_CR30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1067\/moe.2001.112054","volume":"91","author":"EM Ch\u00e1vez","year":"2001","unstructured":"Ch\u00e1vez EM, Borrell LN, Taylor GW, et al. A longitudinal analysis of salivary flow in control subjects and older adults with type 2 diabetes. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:166\u201373.","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"838_CR31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000016423","volume":"32","author":"TO N\u00e4rhi","year":"1998","unstructured":"N\u00e4rhi TO, Vehkalahti MM, Siukosaari P, et al. Salivary findings, daily medication and root caries in the old elderly. Caries Res. 1998;32:5\u20139.","journal-title":"Caries Res"},{"key":"838_CR32","first-page":"845","volume":"78","author":"WC Gonsalves","year":"2008","unstructured":"Gonsalves WC, Wrightson AS, Henry RG. Common oral conditions in older persons. Am Fam Physician. 2008;78:845\u201352.","journal-title":"Am Fam Physician"},{"key":"838_CR33","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/00220345860650090301","volume":"65","author":"A Vissink","year":"1986","unstructured":"Vissink A, De Jong HP, Busscher HJ, et al. Wetting properties of human saliva and saliva substitutes. J Dent Res. 1986;65:1121\u20134.","journal-title":"J Dent Res"},{"key":"838_CR34","first-page":"e190","volume":"24","author":"E Bardellini","year":"2019","unstructured":"Bardellini E, Amadori F, Conti G, et al. Effectiveness of a spray containing 1% malic acid in patients with xerostomia induced by graft-versus-host disease. Med Oral Patol Oral Cir Bucal. 2019;24:e190\u20134.","journal-title":"Med Oral Patol Oral Cir Bucal."},{"key":"838_CR35","unstructured":"Pilocarpine nitrate\u2009\u2265\u200998.5% extra pure. Safety data sheet according to Regulation (EC) No. 1907\/2006 (REACH), amended by 2015\/830\/EU. Article number: 7523. Date of compilation: 2019-10-2. https:\/\/www.carlroth.com\/medias\/SDB-7523-GB-EN.pdf?."},{"key":"838_CR36","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1191\/026921698670435903","volume":"12","author":"AN Davies","year":"1998","unstructured":"Davies AN, Daniels C, Pugh R, et al. A comparison of artificial saliva and pilocarpine in the management of xerostomia in patients with advanced cancer. Palliat Med. 1998;12:105\u201311.","journal-title":"Palliat Med"},{"key":"838_CR37","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/scd.12105","volume":"35","author":"T Tanigawa","year":"2015","unstructured":"Tanigawa T, Yamashita J, Sato T, et al. Efficacy and safety of pilocarpine mouthwash in elderly patients with xerostomia. Spec Care Dent. 2015;35:164\u20139.","journal-title":"Spec Care Dent"},{"key":"838_CR38","first-page":"316","volume":"99","author":"H Olsson","year":"1991","unstructured":"Olsson H, Ax\u00e9ll T. Objective and subjective efficacy of saliva substitutes containing mucin and carboxymethylcellulose. Scand J Dent Res. 1991;99:316\u20139.","journal-title":"Scand J Dent Res"},{"key":"838_CR39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/146642400512500113","volume":"125","author":"DW Matear","year":"2005","unstructured":"Matear DW, Barbaro J. Effectiveness of saliva substitute products in the treatment of dry mouth in the elderly: a pilot study. J R Soc Promot Health. 2005;125:35\u201341.","journal-title":"J R Soc Promot Health."},{"key":"838_CR40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.gerinurse.2015.10.014","volume":"37","author":"S Dalodom","year":"2016","unstructured":"Dalodom S, Lam-Ubol A, Jeanmaneechotechai S, et al. Influence of oral moisturizing jelly as a saliva substitute for the relief of xerostomia in elderly patients with hypertension and diabetes mellitus. Geriatr Nurs. 2016;37:101\u20139.","journal-title":"Geriatr Nurs."},{"key":"838_CR41","doi-asserted-by":"publisher","DOI":"10.1007\/s00784-020-03272-x","author":"J Vinke","year":"2020","unstructured":"Vinke J, Kaper HJ, Vissink A, et al. Dry mouth: saliva substitutes which adsorb and modify existing salivary condition films improve oral lubrication. Clin Oral Investig. 2020. https:\/\/doi.org\/10.1007\/s00784-020-03272-x.","journal-title":"Clin Oral Investig."},{"key":"838_CR42","first-page":"b85","volume":"77","author":"N Su","year":"2011","unstructured":"Su N, Marek CL, Ching V, et al. Caries prevention for patients with dry mouth. J Can Dent Assoc. 2011;77:b85.","journal-title":"J Can Dent Assoc"},{"key":"838_CR43","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.14219\/jada.archive.2013.0057","volume":"144","author":"RJ Weyant","year":"2013","unstructured":"Weyant RJ, Tracy SL, Anselmo TT, et al. Topical fluoride for caries prevention: executive summary of the updated clinical recommendations and supporting systematic review. J Am Dent Assoc. 2013;144:1279\u201391.","journal-title":"J Am Dent Assoc"},{"key":"838_CR44","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.2147\/OPTH.S240057","volume":"14","author":"N Asrini Noor","year":"2020","unstructured":"Asrini Noor N, Rahayu T, Gondhowiardjo TD. Prevalence of dry eye and its subtypes in an elderly population with cataracts in Indonesia. Clin Ophthalmol. 2020;14:2143\u201350.","journal-title":"Clin Ophthalmol."},{"key":"838_CR45","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1167\/iovs.13-11635","volume":"54","author":"CA Fernandez","year":"2013","unstructured":"Fernandez CA, Galor A, Arheart KL, et al. Dry eye syndrome, posttraumatic stress disorder, and depression in an older male veteran population. Invest Ophthalmol Vis Sci. 2013;54:3666\u201372.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"838_CR46","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ajo.2004.10.022","volume":"139","author":"I Kaiserman","year":"2005","unstructured":"Kaiserman I, Kaiserman N, Nakar S, et al. Dry eye in diabetic patients. Am J Ophthalmol. 2005;139:498\u2013503.","journal-title":"Am J Ophthalmol"},{"key":"838_CR47","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1089\/jop.2014.0157","volume":"31","author":"AR Wegener","year":"2015","unstructured":"Wegener AR, Meyer LM, Sch\u00f6nfeld CL. Effect of viscous agents on corneal density in dry eye disease. J Ocul Pharmacol Ther. 2015;31:504\u20138.","journal-title":"J Ocul Pharmacol Ther"},{"key":"838_CR48","doi-asserted-by":"crossref","unstructured":"Vandermeer G, Chamy Y, Pisella PJ. Comparison of objective optical quality measured by double-pass aberrometry in patients with moderate dry eye: normal saline vs. artificial tears: A pilot study. J Fr Ophtalmol. 2018;41:238\u2013245.","DOI":"10.1016\/j.jfo.2017.05.025"},{"key":"838_CR49","doi-asserted-by":"crossref","first-page":"781683","DOI":"10.1155\/2014\/781683","volume":"2014","author":"A Sharma","year":"2014","unstructured":"Sharma A, Hindman HB. Aging: a predisposition to dry eyes. J Ophthalmol. 2014;2014:781683.","journal-title":"J Ophthalmol."},{"key":"838_CR50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jtos.2014.12.001","volume":"13","author":"GN Foulks","year":"2015","unstructured":"Foulks GN, Forstot SL, Donshik PC, et al. Clinical guidelines for management of dry eye associated with Sj\u00f6gren disease. Ocul Surf Ocul Surf. 2015;13:118\u201332.","journal-title":"Ocul Surf Ocul Surf."},{"key":"838_CR51","doi-asserted-by":"crossref","unstructured":"Avisar R, Robinson A, Appel I, et al. Diclofenac sodium, 0.1% (Voltaren Ophtha), versus sodium chloride, 5%, in the treatment of filamentary keratitis. Cornea. 2000;19:145\u20137.","DOI":"10.1097\/00003226-200003000-00005"},{"key":"838_CR52","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1001\/archopht.126.8.1046","volume":"126","author":"HD Perry","year":"2008","unstructured":"Perry HD, Solomon R, Donnenfeld ED, et al. Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol. 2008;126:1046\u201350.","journal-title":"Arch Ophthalmol"},{"key":"838_CR53","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ophtha.2019.01.024","volume":"126","author":"D Wirta","year":"2019","unstructured":"Wirta D, Torkildsen GL, Moreira HR, et al. A clinical phase II study to assess efficacy, safety, and tolerability of waterfree cyclosporine formulation for treatment of dry eye disease. Ophthalmology. 2019;126:792\u2013800.","journal-title":"Ophthalmology"},{"key":"838_CR54","doi-asserted-by":"crossref","unstructured":"Donnenfeld ED, Solomon R, Roberts CW, et al. Cyclosporine 0.05% to improve visual outcomes after multifocal intraocular lens implantation. J Cataract Refract Surg. 2010;36:1095\u2013100.","DOI":"10.1016\/j.jcrs.2009.12.049"},{"key":"838_CR55","doi-asserted-by":"crossref","unstructured":"Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol. 2013;27:167\u201371.","DOI":"10.3341\/kjo.2013.27.3.167"},{"key":"838_CR56","doi-asserted-by":"crossref","unstructured":"Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2019;103:125\u2013131.","DOI":"10.1136\/bjophthalmol-2017-311801"},{"key":"838_CR57","doi-asserted-by":"crossref","unstructured":"Su MY, Perry HD, Barsam A, et al. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1\u00a0year of twice-daily therapy. Cornea. 2011; 30:1098-104.","DOI":"10.1097\/ICO.0b013e318206caee"},{"key":"838_CR58","doi-asserted-by":"crossref","unstructured":"Pan Q, Angelina A, Marrone M, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev. 2017;252.","DOI":"10.1002\/14651858.CD009327.pub3"},{"key":"838_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.209","author":"S Rauz","year":"2017","unstructured":"Rauz S, Koay S-Y, Foot B, et al. The Royal College of ophthalmologists guidelines on serum eye drops for the treatment of severe ocular surface disease: full report. Eye (Lond). 2017. https:\/\/doi.org\/10.1038\/eye.2017.209.","journal-title":"Eye (Lond)."},{"key":"838_CR60","doi-asserted-by":"crossref","unstructured":"Ervin A-M, Law A, Pucker AD, et al. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2017;140.","DOI":"10.1002\/14651858.CD006775.pub3"},{"key":"838_CR61","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1007\/s00296-013-2769-1","volume":"33","author":"W Qiu","year":"2013","unstructured":"Qiu W, Liu Z, Ao M, et al. Punctal plugs versus artificial tears for treating primary Sj\u00f6gren\u2019s syndrome with keratoconjunctivitis sicca: a comparative observation of their effects on visual function. Rheumatol Int. 2013;33:2543\u20138.","journal-title":"Rheumatol Int"},{"key":"838_CR62","doi-asserted-by":"crossref","first-page":"E770","DOI":"10.1097\/OPX.0b013e31824eeb07","volume":"89","author":"OMA Ibrahim","year":"2012","unstructured":"Ibrahim OMA, Dogru M, Kojima T, et al. OCT assessment of tear meniscus after punctal occlusion in dry eye disease. Optom Vis Sci. 2012;89:E770\u20136.","journal-title":"Optom Vis Sci"},{"key":"838_CR63","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ajo.2005.02.031","volume":"140","author":"R Altan-Yaycioglu","year":"2005","unstructured":"Altan-Yaycioglu R, Gencoglu EA, Akova YA, et al. Silicone versus collagen plugs for treating dry eye: results of a prospective randomized trial including lacrimal scintigraphy. Am J Ophthalmol. 2005;140:88\u201393.","journal-title":"Am J Ophthalmol"},{"key":"838_CR64","unstructured":"Jones CE, Anklesaria M, Alan D Gordon AD, et al. Retrospective safety study of the herrick lacrimal plug: a device used to occlude the lacrimal canaliculus. CLAO J. 2002;28:206\u201310."},{"key":"838_CR65","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/ceo.13311","volume":"46","author":"JC Sherwin","year":"2018","unstructured":"Sherwin JC, Ratnarajan G, Elahi B, et al. Effect of a punctal plug on ocular surface disease in patients using topical prostaglandin analogues: a randomized controlled trial. Clin Exp Ophthalmol. 2018;46:888\u201394.","journal-title":"Clin Exp Ophthalmol."},{"key":"838_CR66","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1002\/acr.22974","volume":"69","author":"D Cornec","year":"2017","unstructured":"Cornec D, Devauchelle-Pensec V, Mariette X, et al. Severe Health-Related quality of life impairment in active primary Sj\u00f6gren\u2019s syndrome and Patient-Reported outcomes: data from a large therapeutic trial. Arthritis Care Res. 2017;69:528\u201335.","journal-title":"Arthritis Care Res."},{"key":"838_CR67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3109\/03009742.2016.1153142","volume":"46","author":"JH Koh","year":"2017","unstructured":"Koh JH, Kwok SK, Lee J, et al. Pain, xerostomia, and younger age are major determinants of fatigue in Korean patients with primary Sj\u00f6gren\u2019s syndrome: a cohort study. Scand J Rheumatol. 2017;46:49\u201355.","journal-title":"Scand J Rheumatol"},{"key":"838_CR68","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jbspin.2015.10.005","volume":"83","author":"M Milin","year":"2016","unstructured":"Milin M, Cornec D, Chastaing M, et al. Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sj\u00f6gren\u2019s syndrome. Joint Bone Spine. 2016;83:681\u20135.","journal-title":"Joint Bone Spine."},{"issue":"Suppl 112","key":"838_CR69","first-page":"198","volume":"36","author":"P Brito-Zer\u00f3n","year":"2018","unstructured":"Brito-Zer\u00f3n P, Retamozo S, Ramos-Casals M. Phenotyping Sj\u00f6gren\u2019s syndrome: towards a personalised management of the disease. Clin Exp Rheumatol. 2018;36(Suppl 112):198\u2013209.","journal-title":"Clin Exp Rheumatol"},{"key":"838_CR70","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/0733464812454011","volume":"33","author":"M M\u00e4nty","year":"2014","unstructured":"M\u00e4nty M, Rantanen T, Era P, et al. Fatigue and depressive symptoms in older people. J Appl Gerontol. 2014;33:505\u201314.","journal-title":"J Appl Gerontol."},{"key":"838_CR71","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/S0140-6736(12)61729-2","volume":"380","author":"T Vos","year":"2012","unstructured":"Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163\u201396.","journal-title":"Lancet"},{"key":"838_CR72","unstructured":"Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education Washington (DC): National Academies Press (US); 2011. The National Academies Collection: Reports funded by National Institutes of Health."},{"key":"838_CR73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drudis.2013.08.017","volume":"19","author":"SP Arneric","year":"2014","unstructured":"Arneric SP, Laird JMA, Chappell AS, et al. Tailoring chronic pain treatments for the elderly: are we prepared for the challenge? Drug Discov Today. 2014;19:8\u201317.","journal-title":"Drug Discov Today."},{"key":"838_CR74","doi-asserted-by":"crossref","unstructured":"Geneen LJ, Moore RA, Clarke C, et al. Physical activity and exercise for chronic pain in adults: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017;4.","DOI":"10.1002\/14651858.CD011279.pub2"},{"key":"838_CR75","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/papr.12050","volume":"14","author":"R Andrew","year":"2014","unstructured":"Andrew R, Derry S, Taylor RS, et al. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14:79\u201394.","journal-title":"Pain Pract."},{"key":"838_CR76","doi-asserted-by":"crossref","first-page":"h532","DOI":"10.1136\/bmj.h532","volume":"350","author":"MC Reid","year":"2015","unstructured":"Reid MC, Eccleston C, Pillemer K. Management of chronic pain in older adults. BMJ. 2015;350:h532.","journal-title":"BMJ"},{"key":"838_CR77","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.1046\/j.1532-5415.50.6s.1.x","volume":"50","author":"AGS Panel on Persistent Pain in Older Persons","year":"2002","unstructured":"AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc. 2002;50:S205\u201324.","journal-title":"J Am Geriatr Soc"},{"key":"838_CR78","first-page":"99","volume":"9","author":"BA Ferrell","year":"1997","unstructured":"Ferrell BA, Josephson KR, Pollan AM, et al. A randomized trial of walking versus physical methods for chronic pain management. Aging (Milano). 1997;9:99\u2013105.","journal-title":"Aging (Milano)."},{"key":"838_CR79","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1177\/0269215511423269","volume":"26","author":"K Lihavainen","year":"2012","unstructured":"Lihavainen K, Sipil\u00e4 S, Rantanen T, et al. Effects of comprehensive geriatric assessment and targeted intervention on mobility in persons aged 75\u00a0years and over: a randomized controlled trial. Clin Rehabil. 2012;26:314\u201326.","journal-title":"Clin Rehabil."},{"key":"838_CR80","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.2147\/CIA.S208102","volume":"14","author":"S Cederbom","year":"2019","unstructured":"Cederbom S, Leveille SG, Bergland A. Effects of a behavioral medicine intervention on pain, health, and behavior among community-dwelling older adults: a randomized controlled trial. Clin Interv Aging. 2019;14:1207\u201320.","journal-title":"Clin Interv Aging"},{"key":"838_CR81","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/CIA.S70359","volume":"9","author":"V Quehenberger","year":"2014","unstructured":"Quehenberger V, Cichocki M, Krajic K. Sustainable effects of a low-threshold physical activity intervention on health-related quality of life in residential aged care. Clin Interv Aging. 2014;9:1853\u201364.","journal-title":"Clin Interv Aging"},{"key":"838_CR82","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/ejp.1149","volume":"22","author":"T Hirase","year":"2018","unstructured":"Hirase T, Kataoka H, Nakano J, et al. Effects of a psychosocial intervention programme combined with exercise in community-dwelling older adults with chronic pain: a randomized controlled trial. Eur J Pain. 2018;22:592\u2013600.","journal-title":"Eur J Pain"},{"key":"838_CR83","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/02813432.2016.1160628","volume":"34","author":"S Rapo-Pylkk\u00f6","year":"2016","unstructured":"Rapo-Pylkk\u00f6 S, Haanp\u00e4\u00e4 M, Liira H. Chronic pain among community-dwelling elderly: a population-based clinical study. Scand J Prim Health Care. 2016;34:159\u201364.","journal-title":"Scand J Prim Health Care"},{"key":"838_CR84","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s11096-017-0466-y","volume":"39","author":"MC Kennedy","year":"2017","unstructured":"Kennedy MC, Cousins G, Henman MC. Analgesic use by ageing and elderly patients with chronic non-malignant pain: a qualitative study. Int J Clin Pharm. 2017;39:798\u2013807.","journal-title":"Int J Clin Pharm."},{"key":"838_CR85","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/pds.842","volume":"12","author":"N Moore","year":"2003","unstructured":"Moore N, Charlesworth A, Van Ganse E, et al. Risk factors for adverse events in analgesic drug users: results from the PAIN study. Pharmacoepidemiol Drug Saf. 2003;12:601\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"838_CR86","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.mcna.2016.03.015","volume":"100","author":"MS Loveless","year":"2016","unstructured":"Loveless MS, Fry AL. Pharmacologic therapies in musculoskeletal conditions. Med Clin North Am. 2016;100:869\u201390.","journal-title":"Med Clin North Am"},{"key":"838_CR87","doi-asserted-by":"crossref","unstructured":"Derry S, Conaghan P, Da Silva JAP, et al. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane database Syst Rev. 2016;36.","DOI":"10.1002\/14651858.CD007400.pub3"},{"key":"838_CR88","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1185\/03007995.2015.1092127","volume":"31","author":"T Arai","year":"2015","unstructured":"Arai T, Kashimoto Y, Ukyo Y, et al. Two placebo-controlled, randomized withdrawal studies to evaluate the fentanyl 1-day patch in opioid-na\u00efve patients with chronic pain. Curr Med Res Opin. 2015;31:2207\u201318.","journal-title":"Curr Med Res Opin"},{"key":"838_CR89","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.joca.2011.03.011","volume":"19","author":"PG Conaghan","year":"2011","unstructured":"Conaghan PG, O\u2019Brien CM, Wilson M, et al. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and\/or knee: a randomised trial. Osteoarthritis Cartil. 2011;19:930\u20138.","journal-title":"Osteoarthritis Cartil"},{"issue":"Suppl 112","key":"838_CR90","first-page":"121","volume":"36","author":"A Flores-Ch\u00e1vez","year":"2018","unstructured":"Flores-Ch\u00e1vez A, Kostov B, Solans R, et al. Severe, life-threatening phenotype of primary Sj\u00f6gren\u2019s syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS registry). Clin Exp Rheumatol. 2018;36(Suppl 112):121\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"Suppl 112","key":"838_CR91","first-page":"102","volume":"36","author":"P Brito-Zer\u00f3n","year":"2018","unstructured":"Brito-Zer\u00f3n P, Acar-Denizli N, Ng WF, et al. How immunological profile drives clinical phenotype of primary Sj\u00f6gren\u2019s syndrome at diagnosis: analysis of 10,500 patients (Sj\u00f6gren Big Data Project). Comparative Study. Clin Exp Rheumatol. 2018;36(Suppl 112):102\u201312.","journal-title":"Clin Exp Rheumatol."},{"key":"838_CR92","doi-asserted-by":"crossref","unstructured":"Brito-Zer\u00f3n P, Acar-Denizli N, Ng WF, et al; Sj\u00f6gren Big Data Consortium. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford). 2020;59:2350\u20132359.","DOI":"10.1093\/rheumatology\/kez578"},{"key":"838_CR93","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2014-206418","volume":"75","author":"P Brito-Zer\u00f3n","year":"2016","unstructured":"Brito-Zer\u00f3n P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sj\u00f6gren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. 2016;75:348\u201355.","journal-title":"Ann Rheum Dis"},{"key":"838_CR94","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.intimp.2015.03.027","volume":"27","author":"H Gheitasi","year":"2015","unstructured":"Gheitasi H, Kostov B, Solans R, et al. How are we treating our systemic patients with primary Sj\u00f6gren syndrome? analysis of 1120 patients. Int Immunopharmacol. 2015;27:194\u20139.","journal-title":"Int Immunopharmacol"},{"key":"838_CR95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1874312901409010036","volume":"9","author":"P Sandhya","year":"2015","unstructured":"Sandhya P, Jeyaseelan L, Scofield RH, et al. Clinical characteristics and outcome of primary Sjogren\u2019s syndrome: a large Asian Indian cohort. Open Rheumatol J. 2015;9:36\u201345.","journal-title":"Open Rheumatol J."},{"key":"838_CR96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000422484","volume":"105","author":"G Splendiani","year":"1993","unstructured":"Splendiani G, Costanzi S, Sturniolo A, et al. Treatment of idiopathic glomerulonephritis in the elderly. Personal data. Contrib Nephrol. 1993;105:139\u201343.","journal-title":"Contrib Nephrol."},{"key":"838_CR97","doi-asserted-by":"crossref","unstructured":"Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941\u20137.","DOI":"10.1056\/NEJM199906243402502"},{"key":"838_CR98","first-page":"1321","volume":"8","author":"P Passerini","year":"1993","unstructured":"Passerini P, Como G, Vigan\u00f2 E, et al. Idiopathic membranous nephropathy in the elderly. Nephrol Dial Transpl. 1993;8:1321\u20135.","journal-title":"Nephrol Dial Transpl"},{"key":"838_CR99","doi-asserted-by":"crossref","unstructured":"Chevalet P, Barrier JH, Gl\u00e9marec J, et al. Horton\u2019s disease in elderly patients aged over 75: clinical course, complications of corticotherapy. Comparative study of 164 patients. Towards a reduced initial dose. Rev Med Interne. 2001;22:624\u201330.","DOI":"10.1016\/S0248-8663(01)00399-X"},{"key":"838_CR100","doi-asserted-by":"crossref","first-page":"e19173","DOI":"10.1097\/MD.0000000000019173","volume":"99","author":"D Waki","year":"2020","unstructured":"Waki D, Nishimura K, Tokumasu H, et al. Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: a retrospective observational study. Medicine (Baltimore). 2020;99:e19173.","journal-title":"Medicine (Baltimore)."},{"key":"838_CR101","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","volume":"173","author":"SA Johannesdottir","year":"2013","unstructured":"Johannesdottir SA, Horv\u00e1th-Puh\u00f3 E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med. 2013;173:743\u201352.","journal-title":"JAMA Intern Med."},{"key":"838_CR102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4292\/wjgpt.v7.i1.51","volume":"7","author":"D Nimmons","year":"2016","unstructured":"Nimmons D, Limdi JK. Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther. 2016;7:51\u201365.","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"838_CR103","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.21074","volume":"43","author":"AJ Czaja","year":"2006","unstructured":"Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006;43:532\u20138.","journal-title":"Hepatology"},{"key":"838_CR104","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1572-0241.2001.03782.x","volume":"96","author":"C Schramm","year":"2001","unstructured":"Schramm C, Kanzler S, B\u00fcschenfelde KH, et al. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001;96:1587\u201391.","journal-title":"Am J Gastroenterol"},{"key":"838_CR105","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.2169\/internalmedicine.56.8287","volume":"56","author":"M Morishita","year":"2017","unstructured":"Morishita M, Watanabe H, Yan M, et al. Azathioprine intolerance in japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis. Intern Med. 2017;56:1645\u201350.","journal-title":"Intern Med"},{"key":"838_CR106","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","volume":"143","author":"S Beissert","year":"2007","unstructured":"Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536\u201342.","journal-title":"Arch Dermatol"},{"key":"838_CR107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2215\/CJN.06010809","volume":"5","author":"F Silva","year":"2010","unstructured":"Silva F, Specks U, Kalra S, et al. Mycophenolate mofetil for induction and maintenance of remission in microscopic polyangiitis with mild to moderate renal involvement\u2013a prospective, open-label pilot trial. Clin J Am Soc Nephrol. 2010;5:445\u201353.","journal-title":"Clin J Am Soc Nephrol"},{"key":"838_CR108","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","volume":"160","author":"V Devauchelle-Pensec","year":"2014","unstructured":"Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, et al. Treatment of primary Sj\u00f6gren syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160:233\u201342.","journal-title":"Ann Intern Med"},{"key":"838_CR109","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.40093","volume":"69","author":"SJ Bowman","year":"2017","unstructured":"Bowman SJ, Everett CC, O\u2019Dwyer JL, et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sj\u00f6gren\u2019s syndrome. Arthritis Rheumatol. 2017;69:1440\u201350.","journal-title":"Arthritis Rheumatol."},{"key":"838_CR110","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1136\/ard.2004.029694","volume":"64","author":"J-E Gottenberg","year":"2005","unstructured":"Gottenberg J-E. Tolerance and short-term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis. 2005;64:913\u201320.","journal-title":"Ann Rheum Dis"},{"key":"838_CR111","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2011-200086","volume":"71","author":"A Mekinian","year":"2012","unstructured":"Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sj\u00f6gren\u2019s syndrome with peripheral nervous system involvement: results from the air registry. Ann Rheum Dis. 2012;71:84\u20137.","journal-title":"Ann Rheum Dis"},{"key":"838_CR112","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1136\/annrheumdis-2011-200460","volume":"71","author":"PM Meiners","year":"2012","unstructured":"Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sj\u00f6gren\u2019s syndrome treated with rituximab. Ann Rheum Dis. 2012;71:1297\u2013302.","journal-title":"Ann Rheum Dis"},{"key":"838_CR113","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/ard.2006.057919","volume":"66","author":"R Seror","year":"2007","unstructured":"Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren\u2019s syndrome. Ann Rheum Dis. 2007;66:351\u20137.","journal-title":"Ann Rheum Dis"},{"key":"838_CR114","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/annrheumdis-2012-202293","volume":"72","author":"J-E Gottenberg","year":"2013","unstructured":"Gottenberg J-E, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sj\u00f6gren\u2019s syndrome: results in 78 patients of the autoimmune and rituximab registry. Ann Rheum Dis. 2013;72:1026\u201331.","journal-title":"Ann Rheum Dis"},{"key":"838_CR115","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.21260","volume":"52","author":"J Pijpe","year":"2005","unstructured":"Pijpe J, van Imhoff GW, Spijkervet FKL, et al. Rituximab treatment in patients with primary Sj\u00f6gren\u2019s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740\u201350.","journal-title":"Arthritis Rheum"},{"key":"838_CR116","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","volume":"57","author":"V Devauchelle-Pensec","year":"2007","unstructured":"Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sj\u00f6gren\u2019s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310\u20137.","journal-title":"Arthritis Rheum"},{"key":"838_CR117","doi-asserted-by":"crossref","unstructured":"St. Clair EW, Levesque MC, Prak ETL, et al. Rituximab therapy for primary Sj\u00f6gren\u2019s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65:1097\u2013106.","DOI":"10.1002\/art.37850"},{"key":"838_CR118","doi-asserted-by":"crossref","unstructured":"Carubbi F, Cipriani P, Marrelli A, et al. Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren\u2019s syndrome: a prospective, multi-center, follow-up study. Arthritis Res Ther. 2013;15.","DOI":"10.1186\/ar4359"},{"key":"838_CR119","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","volume":"67","author":"S Dass","year":"2008","unstructured":"Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541\u20134.","journal-title":"Ann Rheum Dis"},{"key":"838_CR120","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","volume":"62","author":"JM Meijer","year":"2010","unstructured":"Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sj\u00f6gren\u2019s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960\u20138.","journal-title":"Arthritis Rheum"},{"key":"838_CR121","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/rheumatology\/kel144","volume":"45","author":"L Fraenkel","year":"2006","unstructured":"Fraenkel L, Rabidou N, Dhar R. Are rheumatologists\u2019 treatment decisions influenced by patients\u2019 age? Rheumatology. 2006;45:1555\u20137.","journal-title":"Rheumatology"},{"key":"838_CR122","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/ard.2005.051144","volume":"65","author":"Z Tutuncu","year":"2006","unstructured":"Tutuncu Z, Reed G, Kremer J, Kavanaugh A. Do patients with older-onset rheumatoid arthritis receive less aggressive treatment? Ann Rheum Dis. 2006;65:1226\u20139.","journal-title":"Ann Rheum Dis"},{"key":"838_CR123","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/rheumatology\/ket224","volume":"52","author":"V Ranganath","year":"2013","unstructured":"Ranganath V, Maranian P, Elashoff D, et al. Comorbidities are associated with poorer outcomes in community patients with rheumatoid arthritis. Rheumatology (Oxford). 2013;52:1809\u201317.","journal-title":"Rheumatology (Oxford)"},{"key":"838_CR124","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/rheumatology\/kep129","volume":"48","author":"B Radovits","year":"2009","unstructured":"Radovits B, Fransen J, Eijsbouts A, et al. Missed opportunities in the treatment of elderly patients with rheumatoid arthritis. Rheumatology. 2009;48:906\u201310.","journal-title":"Rheumatology"},{"key":"838_CR125","doi-asserted-by":"crossref","first-page":"102528","DOI":"10.1016\/j.autrev.2020.102528","volume":"19","author":"L Serhal","year":"2020","unstructured":"Serhal L, Lwin MN, Holroyd C, et al. Rheumatoid arthritis in the elderly: characteristics and treatment considerations. Autoimmun Rev. 2020;19:102528.","journal-title":"Autoimmun Rev"},{"key":"838_CR126","doi-asserted-by":"crossref","unstructured":"De Vita S, Quartuccio L, M Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64:843\u201353.","DOI":"10.1002\/art.34331"},{"key":"838_CR127","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1136\/annrheumdis-2017-212878","volume":"77","author":"P Charles","year":"2018","unstructured":"Charles P, Terrier B, Perrodeau E, et al. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis. 2018;77:1143\u20139.","journal-title":"Ann Rheum Dis"},{"key":"838_CR128","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/acr.23771","volume":"71","author":"HP Tony","year":"2019","unstructured":"Tony HP, Kr\u00fcger K, Cohen SB, et al. Brief Report: safety and immunogenicity of rituximab biosimilar GP 2013 after switch from reference rituximab in patients with active rheumatoid arthritis. Arthritis Care Res (Hoboken). 2019;71:88\u201394.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"838_CR129","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","volume":"18","author":"A Chiappella","year":"2017","unstructured":"Chiappella A, Martelli M, Angelucci E, et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Lancet Oncol. 2017;18:1076\u201388.","journal-title":"Lancet Oncol."},{"key":"838_CR130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"838_CR131","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","volume":"103","author":"S Storti","year":"2018","unstructured":"Storti S, Spina M, Pesce EA, et al. Rituximab plus bendamustine as front-line treatment in frail elderly (>\u200970\u00a0years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. Haematologica. 2018;103:1345\u201350.","journal-title":"Haematologica"},{"key":"838_CR132","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s00280-019-03775-9","volume":"83","author":"E Baudry","year":"2019","unstructured":"Baudry E, Huguet S, Couderc AL, et al. Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP. Cancer Chemother Pharmacol. 2019;83:775\u201385.","journal-title":"Cancer Chemother Pharmacol"},{"key":"838_CR133","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3899\/jrheum.110077","volume":"38","author":"RP Pollard","year":"2011","unstructured":"Pollard RP, Pijpe J, Bootsma H, et al. Treatment of mucosa-associated lymphoid tissue lymphoma in Sjogren\u2019s syndrome: a retrospective clinical study. J Rheumatol. 2011;38:2198\u2013208.","journal-title":"J Rheumatol"},{"key":"838_CR134","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","volume":"32","author":"G Held","year":"2014","unstructured":"Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-021-00838-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-021-00838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,30]],"date-time":"2021-03-30T02:09:17Z","timestamp":1617070157000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-021-00838-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,23]]},"references-count":134,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["838"],"URL":"https:\/\/doi.org\/10.1007\/s40266-021-00838-6","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,23]]},"assertion":[{"value":"23 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BAF and SJB have received support from the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"BAF: consultancy for Novartis, Roche, BMS, Servier, Galapagos and Janssen. TM: working as Medical Advisor for Novartis. SJB: consultancy with Abbvie, Galapagos and Novartis. AK: received a grant\/research support from Sandoz. The rest of the authors declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable to a review.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data were sourced from academic journals, are listed in the references, and are available to the public.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All listed authors meet the common criteria for authorship; each contributed significantly to the intellectual creation of this project, as well as the writing and editing of this manuscript. The author order has been approved by all authors, and the final manuscript has been read and approved by all authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}